<span item_type="fundamental" item_id="5260b8b08c50042111a8085884cc0111" counter_id="ST/US/HUMAW" env="prod"></span><span item_type="announcement" item_id="581936185994386689" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 753 K.</p><p>EPS: As of FY2025 Q3, the actual value is USD -0.11.</p><p>EBIT: As of FY2025 Q3, the actual value is USD -24.39 M.</p><p></p><h3>Segment Revenue</h3><ul><li>Total revenue for the third quarter of 2025 was $0.8 million, with $0.7 million from U.S. sales of Symvess and $0.1 million from a research collaboration.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1818382/000110465925109718/tm2530973d1_ex99-1.htm"></span></li><li>Revenue for the first nine months of 2025 was $1.6 million, with $0.9 million from U.S. sales of Symvess and $0.6 million from the research collaboration.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1818382/000110465925109718/tm2530973d1_ex99-1.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li>Cost of goods sold was $0.3 million for the third quarter and $0.6 million for the first nine months of 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1818382/000110465925109718/tm2530973d1_ex99-1.htm"></span></li><li>Research and development expenses decreased to $17.3 million for the third quarter of 2025 from $22.9 million in the same period of 2024, and to $54.7 million for the first nine months of 2025 from $67.9 million in the same period of 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1818382/000110465925109718/tm2530973d1_ex99-1.htm"></span></li><li>Selling, general and administrative expenses were $7.6 million for the third quarter of 2025, up from $7.3 million in the same period of 2024, and $23.6 million for the first nine months of 2025, up from $18.4 million in the same period of 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1818382/000110465925109718/tm2530973d1_ex99-1.htm"></span></li><li>Net loss was $17.5 million for the third quarter of 2025, compared to $39.2 million for the same period in 2024, and $16.0 million for the first nine months of 2025, compared to $127.8 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1818382/000110465925109718/tm2530973d1_ex99-1.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>The company reported cash, cash equivalents, and restricted cash of $19.8 million as of September 30, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1818382/000110465925109718/tm2530973d1_ex99-1.htm"></span></li><li>Total net cash used in operating activities was $78.9 million for the first nine months of 2025, compared to $71.5 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1818382/000110465925109718/tm2530973d1_ex99-1.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li>The company completed the sale of common stock and warrants resulting in net proceeds of approximately $56.5 million subsequent to September 30, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1818382/000110465925109718/tm2530973d1_ex99-1.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>Humacyte plans to advance the Coronary Tissue Engineered Vessel (CTEV) into a first-in-human study in CABG in 2026, with an IND application submitted to the FDA.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1818382/000110465925109718/tm2530973d1_ex99-1.htm"></span></li><li>The company aims to submit a supplemental BLA for the ATEV in dialysis in the second half of 2026, subject to interim results from ongoing trials.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1818382/000110465925109718/tm2530973d1_ex99-1.htm"></span></li><li>Humacyte is expanding its intellectual property estate with a new U.S. patent for its bioengineered esophagus, complementing existing patents for urinary conduits and tracheas.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1818382/000110465925109718/tm2530973d1_ex99-1.htm"></span></li></ul>

Humacyte - CW27 | 8-K: FY2025 Q3 Revenue: USD 753 K